

Disclaimer

This presentation is for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities of MustGrow Biologics Corp. ("MustGrow") nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. MustGrow makes certain filings with the Canadian securities regulatory authorities, all of which are available under our SEDAR+ profile at www.sedarplus.ca. For a more complete discussion of the risk factors affecting our business, please refer to these filings.

Projections, estimates, industry data and information contained in this presentation, including the size of and growth of certain markets, are based on information from third-party sources and management estimates. Although MustGrow believes that its third party-sources are reliable, MustGrow cannot guarantee the accuracy or completeness of its sources. MustGrow's management estimates are derived from third-party sources, publicly available information, MustGrow's knowledge of its industry and assumptions based on such information and knowledge. MustGrow's management estimates have not been verified by any independent source. All of the projections, estimates, market data and industry information used in this presentation involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such information. In addition, projections, estimates and assumptions relating to MustGrow's and its industry's future performance are necessarily subject to a high degree of uncertainty and risk, that could cause future performance to differ materially from MustGrow's expressed projections, estimates and assumptions or those provided by third parties.

Our public communications, including this presentation, and SEDAR+ filings, may contain statements related to future, not past, events. These forward-looking statements are based upon current beliefs and expectations of MustGrow's management and are subject to significant risks and uncertainties. These forward-looking statements often, but not always, may be identified by the use of words such as "believes," "estimates," "anticipates," "targets," "expects," "plans," "projects," "intends," "predicts," "may," "could," "might," "will," "should," "approximately," "potential" or, in each case, their negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. Such statements reflect MustGrow's current views with respect to future events and are subject to certain risks, uncertainties, and assumptions (known and unknown). Many factors could cause MustGrow's actual results, performance, or achievements to vary from those described herein. By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics, and regulatory and scientific developments and depend on the economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated or not at all. Although we believe that we have a reasonable basis for each forward-looking statement contained in this presentation, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this presentation. Moreover, MustGrow operates in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that MustGrow may face. Except as required by applicable law

This presentation may contain trademarks, service marks, trade names and copyrights of other companies, which are the property of their respective owners. Solely for convenience, some of the trademarks, service marks, trade names and copyrights referred to in this presentation may be listed without the TM, © or ® symbols, but MustGrow will assert, to the fullest extent under applicable law, the rights of the applicable owners, if any, to these trademarks, service marks, trade names and copyrights.

The #1 thing every farmer cares about is growing a crop and protecting it from unwanted pests and disease

Traditional chemical pesticides are unhealthy, and consumers are demanding safer and more sustainable products

MustGrow is a fully-integrated provider of biological and regenerative agriculture solutions to support sustainable farming

Massive Market

- US\$380 billion (2032 est.) global fertilizer & pesticide market
- Biologics & regenerative products are the fastest growing segment

Partnership mating Bayer to

Commercial

 Estimating Bayer to invest US\$35-40 million to commercialize in EMEA





Revenues for 1H-2025 \$6.6M

NexusBioAg





Tight Capital Structure

- 58.9M shares outstanding
- C\$45M market cap
- Low capex model
- 20% mgmt. & advisor ownership

Sustainable Agriculture is the Future of Food Security



Increased Regulation on Synthetic Chemicals...

162 countries have banned 460 pesticide active ingredients, and the list continues to grow USA is currently using 72 pesticides that are currently banned, or will be banned in Europe

- PAN - Pesticide Action Network; 2. <u>www.fao.org/plant-production-protection/about/en</u>





... Commitment to Organic Solutions & Growth

Bayer expects to access more than 100 billion euros in these adjacent markets annually in effect doubling the division's potential market which today stands at more than 100 billion euro for the core portfolio alone. Importantly, by the middle of the next decade, Bayer envisions shaping regenerative agriculture on more than 400 million acres, built on the foundation of its leading agriculture input solutions.


- Bayer, June 20, 2023

EU Organic Action Plan - 25% Organic Acres by 2030 On March 25, 2021, the European Commission published the Farm to Fork Strategy Action Plan with a target of 25% of EU land under organic farming by 2030.

- European Commission, March 25, 2021



Large and Growing Global Demand for Natural Biologics (estimated 2032)



		BIOCONTROL	BIOFERTILITY
	MARKET SIZE	US\$20.2B (2033)	US\$6.3B (2032)
	GROWTH RATE	15.0%	12.2%
	INDUSTRY DYNAMICS	 Replacements for Synthetic Pesticides and Fertilizers needed Organic demand / acres growing Soil and environmental health are critical 	

Sources:

https://www.bayer.com/media/en-us/bayer-sees-more-than-doubling-of-accessible-markets-and-potential-to-shape-regenerative-agriculture-on-more-than-400-million-acres/;

https://agriculture.ec.europa.eu/farming/organic-farming/organic-action-plan_en; https://www.precedenceresearch.com/fertilizer-market; https://www.globenewswire.com/news-release/2024/04/29/2871551/0/en/Biocontrol-Agents-Market-

<u>Share-Projections-CAGR-of-15-Envisions-Market-Size-of-20-22-Billion-by-2033.html</u>; https://www.marketresearchfuture.com/reports/soil-amendment-market-22873#:~:text=Global%20Soil%20Amendment%20Market%20Overview&text=The%20Soil%20Amendment%20Market%20Industry,period%20(2024%20%2D%202032)

MustGrow Biologics Corp.

MustGrow's Commercial Sales Expansion

Revenue Segment	Assets	High Growth Commercial Sales	Why?
North American Biofertilizer / Biocontrol	TerraSANTE TerraMG	 TerraSante biofertilizer sales have started in US (including California) TerraMG biocontrol registrations hopefully by 2026 	 5.6 million acres in US of high value crops (multiple crops per acre per year) Targeting 30 million acres in Canada for Canola and pulse crops (sold through distribution below)
Commercial Licensing of Biocontrol in EMEA & in ROW TerraMG	➤ EMEA BAYER R Asia / SA Other?	 Upfront payment Milestone payments Royalty on gross sales Option to supply extract on a cost + basis Initial registration expected in 2027 	Large Ag Chems are moving into the biological and regenerative agriculture space to replace their synthetic product-lines, which are being banned or deregistered
Distribution	NexusBioAg	 Historic sales of \$15-20 million Over 40 product lines that help farmers grow crops Targeting 5 new products being added in 2025 Distributor of RhizoSorb® - reduced rate phosphate 	 Fully integrated regenerative ag sales and marketing platform Synergistic sales of TerraMG Biocontrol in Canada Opportunity for high growth sales
New Applications & Technologies	➤ 112 patents issued & pending	 High value animal feed (late development) Postharvest biocontrol (late development) SCN- (early development) HBA (early development) Animal health (early development) Human health (early development) 	 Mustard has lots of potential applications If validated, MustGrow will partner with key industry participants to develop and commercialize

Potential Milestones & Catalysts
















TerraSanteTM Biofertility: U.S. Sales Strategy





Registered in Key States

- California, Florida, Arizona, Idaho, Oregon, Washington
- Organically certified

Toll Manufacturing Production

- Produced in Canada
- Assessing US and Asian production
- Low capex model

Targeting High Value Crops

- Fruit & vegetables; tree, nut & vine; root & tuber; potatoes
- 5.6 million acres in US*
- 187,000 acres of organic*
- Opportunity for multiple crops WITH multiple applications annually per acre of TerraSanteTM
 - ie: strawberries can be grown 2-4x per year/acre

Revenue Strategy





Commercial scale ramp-up to follow
















MustGrow Biologics Corp.



TerraSanteTM Biofertility: US Value Proposition



- 5.6 million of targetable high value crops acres (incl. 187,000 organic acres)
- Every 50,000 acres (0.9% penetration) represents an estimated C\$39 million product revenue
- Estimated product revenue per acre of C\$775

Illustrative Product Revenue (C\$ Millions)						
% Pentration	Penetration (Acres)	2028 Rev	Discounted Rev*			
0.9%	50,000	\$39 MM	\$19 MM			
1.8%	100,000	\$78 MM	\$37 MM			
2.7%	150,000	\$117 MM	\$56 MM			
3.5%	200,000	\$155 MM	\$75 MM			
4.4%	250,000	\$194 MM	\$94 MM			

Illustrative Sample:

- TerraSante product sales on 150,000 acres could generate \$117 million revenue
- Discounted by 4 years at 20% per year = \$56 million discounted revenue



^{20%} discount rate; discounted 4 years



Penetration acres and corresponding revenues are for illustrative purposes; not projections

Per share values are calculated using 60 million fully-diluted shares (rounded)

[•] Revenue multiples are for illustrative purposes; not share price projections

Gross margins initially at >20%; Potentially expanding to >50% at scale (>50,000 acres)



TerraMGTM Biocontrol

Preplant soil fumigation

- Treating soil borne diseases and pests such as nematodes
- Replacement for Chloropicrin, Metam Sodium, etc.
- Organic

Registrations Coming Soon

- MustGrow is registering in Canada & US:
 - Estimating 2026
- MustGrow is partnering in ROW:
 - Exclusive commercial license with Bayer in EMEA
 - **▶** Estimating first registration in 2027
 - Seeking exclusive commercial license in LATAM & Asia



Toll Manufacturing Production

- Produced in Canada
- Assessing US and Asian production
- Low capex model

2024 Field Trial Study on Canola

Treatment rate with TerraMG: 2 L/acre (4.8 L/Ha)

Yield Results

- 7.28 bushels/acre yield advantage for TerraMG
- C\$98.00/acre revenue increase (at current market price)
- Reduction of Clubroot Spores post-application and post-harvest

MustGrow's TerraMG

Outside Trial Area

51.77 bushels/acre

44.49 bushels/acre



Bayer Commercial Agreement

- Exclusive Commercial License Agreement for preplant biopesticide (TerraMG) and bioherbicide
- Region: Europe, Middle East and Africa (EMEA); Global ROFR on bananas

WHY

- Current chemicals under pressure from governments and consumers
- Organic acres continue to grow across the region
- EU's 25% organic production ambition by 2030)



- Bayer could invest US\$35-40 million to commercialize TerraMG*:
 - Upfront and milestone payments to MustGrow
 - Development & registration costs
- Post registration, MustGrow to receive:
 - Gross royalty
 - Cost+ on supply of active ingredient

NEXT STEPS

- Registration activities in multiple countries
- Additional development work on new formulations
- Goal of first registration in 3 years

NexusBioAg – Agriculture Sales & Distribution

• Fully integrated biological and regenerative agriculture sales and marketing platform

High Growth

Lever MustGrow relationships to license or acquire third party products





Distribution

Sales channel for MustGrow's own proprietary products (once registered)



Over 40 Products from Reputable Brands

























Capital Structure

TSXV:MGRO OTCQB:MGROF FRA:0C0



Common Shares Outstanding		
Warrants		
Options/RSUs/DSUs		
Convertible debentures		
Fully-Diluted Shares Outstanding		
Market Cap (CAD)		
Mgmt. & Advisor Ownership		
Average Volume (3 month)		
Previous Capital Spent (CAD)		
Cash Position at June 30, 2025 (CAD)		
Debt (CAD)*		

58,854,285
4,949,387
3,536,397
133.332
67,473,401
\$45,000,000
20%
40,000
\$30,000,000
\$1.820,955
\$517,991

[•] Debt has no maturity; no interest payable; no scheduled principal payments. Due upon change of control of MustGrow and/or certain revenue milestones.

Experienced Management Team

Lean executive team has the vision, energy and experience to execute



Corey Giasson, MBA CEO & Director

- 6 years with Company
- 20+ Years Experience

Anglo Potash PotashCorp



Colin Bletsky
COO & Director

- 6 years with Company
- 25+ Years Experience

novozymes syngenta



Todd Lahti, CFA, CPA, CA

- 11 years with Company
- 35+ Years Experience



PartnerRe





Ben LibbyGeneral Manager - NexusBioAg

- 8 years with NexusBioAg
- 35+ Years Experience

novozymes.***



Board of Directors and Advisory Team

Board of Directors



Chairman



Laura Westby, JD

Director



Matt Kowalski
Director



David Borecky, CPA, CA



Tom Flow
Director

Advisors



Dr. David MaenzProduction Advisor



Mark Hetherington
Formulations Advisor



Dr. Matthew J. MorraScientific Advisor



Jamieson Bondarenko, CFA, CMT
Capital Markets Advisor